#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Debilitating , unexplained provoked localized vulvar pain or vulvodynia affects a significant proportion ( ~8 % ) of women and is epidemiologically linked to a history of both seasonal and contact allergies .
2-1	16-28	Debilitating	abstract[2]|abstract[3]	new[2]|new[3]	coref|coref	4-22[22_2]|5-34[37_3]
2-2	29-30	,	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-3	31-42	unexplained	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-4	43-51	provoked	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-5	52-61	localized	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-6	62-68	vulvar	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-7	69-73	pain	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-8	74-76	or	abstract[3]	new[3]	_	_
2-9	77-87	vulvodynia	abstract[3]|abstract	new[3]|new	coref	11-22
2-10	88-95	affects	_	_	_	_
2-11	96-97	a	abstract[5]	new[5]	appos	2-15[6_5]
2-12	98-109	significant	abstract[5]	new[5]	_	_
2-13	110-120	proportion	abstract[5]	new[5]	_	_
2-14	121-122	(	_	_	_	_
2-15	123-125	~8	abstract[6]	giv[6]	_	_
2-16	126-127	%	abstract[6]	giv[6]	_	_
2-17	128-129	)	_	_	_	_
2-18	130-132	of	_	_	_	_
2-19	133-138	women	person	new	_	_
2-20	139-142	and	_	_	_	_
2-21	143-145	is	_	_	_	_
2-22	146-163	epidemiologically	_	_	_	_
2-23	164-170	linked	_	_	_	_
2-24	171-173	to	_	_	_	_
2-25	174-175	a	abstract[8]	new[8]	_	_
2-26	176-183	history	abstract[8]	new[8]	_	_
2-27	184-186	of	abstract[8]	new[8]	_	_
2-28	187-191	both	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-29	192-200	seasonal	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-30	201-204	and	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-31	205-212	contact	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-32	213-222	allergies	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-33	223-224	.	_	_	_	_

#Text=Vulvar biopsies from diagnosed patients show increases in mast cells and nerves .
3-1	225-231	Vulvar	abstract[10]	new[10]	_	_
3-2	232-240	biopsies	abstract[10]	new[10]	_	_
3-3	241-245	from	abstract[10]	new[10]	_	_
3-4	246-255	diagnosed	abstract[10]|person[11]	new[10]|new[11]	_	_
3-5	256-264	patients	abstract[10]|person[11]	new[10]|new[11]	_	_
3-6	265-269	show	_	_	_	_
3-7	270-279	increases	event[12]	new[12]	_	_
3-8	280-282	in	event[12]	new[12]	_	_
3-9	283-287	mast	event[12]|object|object[14]	new[12]|new|new[14]	coref|coref	5-42|5-42[40_14]
3-10	288-293	cells	event[12]|object[14]	new[12]|new[14]	_	_
3-11	294-297	and	event[12]	new[12]	_	_
3-12	298-304	nerves	event[12]|object	new[12]|new	_	_
3-13	305-306	.	_	_	_	_

#Text=To recapitulate and dissect the pathobiology of allergy-driven tactile sensitivity and to inform novel therapies , we established mouse models of allergy-driven genital pain .
4-1	307-309	To	_	_	_	_
4-2	310-322	recapitulate	_	_	_	_
4-3	323-326	and	_	_	_	_
4-4	327-334	dissect	_	_	_	_
4-5	335-338	the	abstract[16]	new[16]	_	_
4-6	339-351	pathobiology	abstract[16]	new[16]	_	_
4-7	352-354	of	abstract[16]	new[16]	_	_
4-8	355-369	allergy-driven	abstract[16]|abstract[17]	new[16]|new[17]	coref	15-43[143_17]
4-9	370-377	tactile	abstract[16]|abstract[17]	new[16]|new[17]	_	_
4-10	378-389	sensitivity	abstract[16]|abstract[17]	new[16]|new[17]	_	_
4-11	390-393	and	_	_	_	_
4-12	394-396	to	_	_	_	_
4-13	397-403	inform	_	_	_	_
4-14	404-409	novel	abstract[18]	new[18]	_	_
4-15	410-419	therapies	abstract[18]	new[18]	_	_
4-16	420-421	,	_	_	_	_
4-17	422-424	we	person	acc	ana	5-1
4-18	425-436	established	_	_	_	_
4-19	437-442	mouse	animal|abstract[21]	new|new[21]	coref|coref	12-4|12-1[113_21]
4-20	443-449	models	abstract[21]	new[21]	_	_
4-21	450-452	of	abstract[21]	new[21]	_	_
4-22	453-467	allergy-driven	abstract[21]|abstract[22]	new[21]|giv[22]	coref	5-34[36_22]
4-23	468-475	genital	abstract[21]|abstract[22]	new[21]|giv[22]	_	_
4-24	476-480	pain	abstract[21]|abstract[22]	new[21]|giv[22]	_	_
4-25	481-482	.	_	_	_	_

#Text=We have shown that contact hypersensitivity to the commonly used laboratory haptens oxazolone ( Ox ) on the labiar skin or dinitrofluorobenzene ( DNFB ) on the labiar skin or vaginal canal induces persistent tactile genital pain and increased accumulation of mast cells in the labiar tissues of outbred , female ND4 mice well beyond the resolution of visible inflammation .
5-1	483-485	We	person	giv	ana	7-3
5-2	486-490	have	_	_	_	_
5-3	491-496	shown	_	_	_	_
5-4	497-501	that	_	_	_	_
5-5	502-509	contact	abstract|abstract[25]	new|new[25]	coref|coref	7-20|7-21[0_25]
5-6	510-526	hypersensitivity	abstract[25]	new[25]	_	_
5-7	527-529	to	abstract[25]	new[25]	_	_
5-8	530-533	the	abstract[25]|substance[28]	new[25]|new[28]	_	_
5-9	534-542	commonly	abstract[25]|substance[28]	new[25]|new[28]	_	_
5-10	543-547	used	abstract[25]|substance[28]	new[25]|new[28]	_	_
5-11	548-558	laboratory	abstract[25]|place|animal[27]|substance[28]	new[25]|new|new[27]|new[28]	_	_
5-12	559-566	haptens	abstract[25]|animal[27]|substance[28]	new[25]|new[27]|new[28]	_	_
5-13	567-576	oxazolone	abstract[25]|substance[28]	new[25]|new[28]	_	_
5-14	577-578	(	_	_	_	_
5-15	579-581	Ox	person	new	_	_
5-16	582-583	)	_	_	_	_
5-17	584-586	on	_	_	_	_
5-18	587-590	the	object[30]	new[30]	coref	5-27[33_30]
5-19	591-597	labiar	object[30]	new[30]	_	_
5-20	598-602	skin	object[30]	new[30]	_	_
5-21	603-605	or	_	_	_	_
5-22	606-626	dinitrofluorobenzene	substance	new	appos	5-24
5-23	627-628	(	_	_	_	_
5-24	629-633	DNFB	substance	giv	_	_
5-25	634-635	)	_	_	_	_
5-26	636-638	on	_	_	_	_
5-27	639-642	the	object[33]|object[34]	giv[33]|new[34]	coref|coref	9-31[89_33]|9-31[90_34]
5-28	643-649	labiar	object[33]|object[34]	giv[33]|new[34]	_	_
5-29	650-654	skin	object[33]|object[34]	giv[33]|new[34]	_	_
5-30	655-657	or	object[34]	new[34]	_	_
5-31	658-665	vaginal	object[34]|place[35]	new[34]|new[35]	coref	6-21[53_35]
5-32	666-671	canal	object[34]|place[35]	new[34]|new[35]	_	_
5-33	672-679	induces	_	_	_	_
5-34	680-690	persistent	abstract[36]|abstract[37]	giv[36]|giv[37]	coref	6-25[54_36]
5-35	691-698	tactile	abstract[36]|abstract[37]	giv[36]|giv[37]	_	_
5-36	699-706	genital	abstract[36]|abstract[37]	giv[36]|giv[37]	_	_
5-37	707-711	pain	abstract[36]|abstract[37]	giv[36]|giv[37]	_	_
5-38	712-715	and	abstract[37]	giv[37]	_	_
5-39	716-725	increased	abstract[37]|abstract[38]	giv[37]|new[38]	_	_
5-40	726-738	accumulation	abstract[37]|abstract[38]	giv[37]|new[38]	_	_
5-41	739-741	of	abstract[37]|abstract[38]	giv[37]|new[38]	_	_
5-42	742-746	mast	abstract[37]|abstract[38]|object|object[40]	giv[37]|new[38]|giv|giv[40]	coref|coref	6-5|6-4[48_40]
5-43	747-752	cells	abstract[37]|abstract[38]|object[40]	giv[37]|new[38]|giv[40]	_	_
5-44	753-755	in	abstract[37]|abstract[38]|object[40]	giv[37]|new[38]|giv[40]	_	_
5-45	756-759	the	abstract[37]|abstract[38]|object[40]|object[41]	giv[37]|new[38]|giv[40]|new[41]	_	_
5-46	760-766	labiar	abstract[37]|abstract[38]|object[40]|object[41]	giv[37]|new[38]|giv[40]|new[41]	_	_
5-47	767-774	tissues	abstract[37]|abstract[38]|object[40]|object[41]	giv[37]|new[38]|giv[40]|new[41]	_	_
5-48	775-777	of	abstract[37]|abstract[38]	giv[37]|new[38]	_	_
5-49	778-785	outbred	abstract[37]|abstract[38]|animal[43]	giv[37]|new[38]|new[43]	coref	7-29[70_43]
5-50	786-787	,	abstract[37]|abstract[38]|animal[43]	giv[37]|new[38]|new[43]	_	_
5-51	788-794	female	abstract[37]|abstract[38]|animal[43]	giv[37]|new[38]|new[43]	_	_
5-52	795-798	ND4	abstract[37]|abstract[38]|abstract|animal[43]	giv[37]|new[38]|new|new[43]	coref	7-29
5-53	799-803	mice	abstract[37]|abstract[38]|animal[43]	giv[37]|new[38]|new[43]	_	_
5-54	804-808	well	abstract[44]	new[44]	_	_
5-55	809-815	beyond	abstract[44]	new[44]	_	_
5-56	816-819	the	abstract[44]	new[44]	_	_
5-57	820-830	resolution	abstract[44]	new[44]	_	_
5-58	831-833	of	abstract[44]	new[44]	_	_
5-59	834-841	visible	abstract[44]|abstract[45]	new[44]|new[45]	coref	15-33[139_45]
5-60	842-854	inflammation	abstract[44]|abstract[45]	new[44]|new[45]	_	_
5-61	855-856	.	_	_	_	_

#Text=Chemical depletion of labiar mast cells reduced Ox-driven painful responses and therapeutic topical administration of Δ-9-tetrahydrocannabinol ( THC ) in the vaginal canal alleviated DNFB-induced pain and reduced numbers of accumulated mast cells in the affected tissue .
6-1	857-865	Chemical	event[46]	new[46]	_	_
6-2	866-875	depletion	event[46]	new[46]	_	_
6-3	876-878	of	event[46]	new[46]	_	_
6-4	879-885	labiar	event[46]|object[48]	new[46]|giv[48]	coref	6-31[57_48]
6-5	886-890	mast	event[46]|object|object[48]	new[46]|giv|giv[48]	coref	6-32
6-6	891-896	cells	event[46]|object[48]	new[46]|giv[48]	_	_
6-7	897-904	reduced	_	_	_	_
6-8	905-914	Ox-driven	event[49]	new[49]	coref	9-22[86_49]
6-9	915-922	painful	event[49]	new[49]	_	_
6-10	923-932	responses	event[49]	new[49]	_	_
6-11	933-936	and	_	_	_	_
6-12	937-948	therapeutic	event[50]	new[50]	_	_
6-13	949-956	topical	event[50]	new[50]	_	_
6-14	957-971	administration	event[50]	new[50]	_	_
6-15	972-974	of	event[50]	new[50]	_	_
6-16	975-999	Δ-9-tetrahydrocannabinol	event[50]|substance	new[50]|new	appos	6-18
6-17	1000-1001	(	event[50]	new[50]	_	_
6-18	1002-1005	THC	event[50]|substance	new[50]|giv	coref	16-13
6-19	1006-1007	)	event[50]	new[50]	_	_
6-20	1008-1010	in	event[50]	new[50]	_	_
6-21	1011-1014	the	event[50]|place[53]	new[50]|giv[53]	coref	16-16[150_53]
6-22	1015-1022	vaginal	event[50]|place[53]	new[50]|giv[53]	_	_
6-23	1023-1028	canal	event[50]|place[53]	new[50]|giv[53]	_	_
6-24	1029-1039	alleviated	_	_	_	_
6-25	1040-1052	DNFB-induced	abstract[54]	giv[54]	coref	7-24[68_54]
6-26	1053-1057	pain	abstract[54]	giv[54]	_	_
6-27	1058-1061	and	_	_	_	_
6-28	1062-1069	reduced	_	_	_	_
6-29	1070-1077	numbers	abstract[55]	new[55]	_	_
6-30	1078-1080	of	abstract[55]	new[55]	_	_
6-31	1081-1092	accumulated	abstract[55]|object[57]	new[55]|giv[57]	coref	15-39[142_57]
6-32	1093-1097	mast	abstract[55]|object|object[57]	new[55]|giv|giv[57]	coref	15-39
6-33	1098-1103	cells	abstract[55]|object[57]	new[55]|giv[57]	_	_
6-34	1104-1106	in	abstract[55]|object[57]	new[55]|giv[57]	_	_
6-35	1107-1110	the	abstract[55]|object[57]|object[58]	new[55]|giv[57]|new[58]	coref	9-28[0_58]
6-36	1111-1119	affected	abstract[55]|object[57]|object[58]	new[55]|giv[57]|new[58]	_	_
6-37	1120-1126	tissue	abstract[55]|object[57]|object[58]	new[55]|giv[57]|new[58]	_	_
6-38	1127-1128	.	_	_	_	_

#Text=Here , we examined the potential of a common household chemical , 2-methyl-4-isothiazolin-3-one/methylisothiazolinone ( MI ) , to induce contact hypersensitivity reactions and consequent allergy-driven genital pain in ND4 female outbred mice .
7-1	1129-1133	Here	_	_	_	_
7-2	1134-1135	,	_	_	_	_
7-3	1136-1138	we	person	giv	ana	12-1
7-4	1139-1147	examined	_	_	_	_
7-5	1148-1151	the	abstract[60]	new[60]	_	_
7-6	1152-1161	potential	abstract[60]	new[60]	_	_
7-7	1162-1164	of	abstract[60]	new[60]	_	_
7-8	1165-1166	a	abstract[60]|substance[62]	new[60]|new[62]	appos	7-13[0_62]
7-9	1167-1173	common	abstract[60]|substance[62]	new[60]|new[62]	_	_
7-10	1174-1183	household	abstract[60]|place|substance[62]	new[60]|new|new[62]	coref	8-15
7-11	1184-1192	chemical	abstract[60]|substance[62]	new[60]|new[62]	_	_
7-12	1193-1194	,	_	_	_	_
7-13	1195-1246	2-methyl-4-isothiazolin-3-one/methylisothiazolinone	substance	giv	appos	7-15
7-14	1247-1248	(	_	_	_	_
7-15	1249-1251	MI	substance	giv	coref	8-1
7-16	1252-1253	)	_	_	_	_
7-17	1254-1255	,	_	_	_	_
7-18	1256-1258	to	_	_	_	_
7-19	1259-1265	induce	_	_	_	_
7-20	1266-1273	contact	abstract|event[67]	giv|new[67]	_	_
7-21	1274-1290	hypersensitivity	abstract|event[67]	giv|new[67]	_	_
7-22	1291-1300	reactions	event[67]	new[67]	_	_
7-23	1301-1304	and	_	_	_	_
7-24	1305-1315	consequent	abstract[68]	giv[68]	coref	10-24[99_68]
7-25	1316-1330	allergy-driven	abstract[68]	giv[68]	_	_
7-26	1331-1338	genital	abstract[68]	giv[68]	_	_
7-27	1339-1343	pain	abstract[68]	giv[68]	_	_
7-28	1344-1346	in	_	_	_	_
7-29	1347-1350	ND4	abstract|animal[70]	giv|giv[70]	coref	15-30[0_70]
7-30	1351-1357	female	animal[70]	giv[70]	_	_
7-31	1358-1365	outbred	animal[70]	giv[70]	_	_
7-32	1366-1370	mice	animal[70]	giv[70]	_	_
7-33	1371-1372	.	_	_	_	_

#Text=MI is a biocide preservative present in soaps , shampoos , vaginal washes , household cleaners , and paints .
8-1	1373-1375	MI	substance	giv	coref	8-3[73_0]
8-2	1376-1378	is	_	_	_	_
8-3	1379-1380	a	substance[73]	giv[73]	coref	9-12[0_73]
8-4	1381-1388	biocide	substance|substance[73]	new|giv[73]	_	_
8-5	1389-1401	preservative	substance[73]	giv[73]	_	_
8-6	1402-1409	present	substance[73]	giv[73]	_	_
8-7	1410-1412	in	_	_	_	_
8-8	1413-1418	soaps	substance	new	_	_
8-9	1419-1420	,	_	_	_	_
8-10	1421-1429	shampoos	substance	new	_	_
8-11	1430-1431	,	_	_	_	_
8-12	1432-1439	vaginal	object[76]	new[76]	_	_
8-13	1440-1446	washes	object[76]	new[76]	_	_
8-14	1447-1448	,	_	_	_	_
8-15	1449-1458	household	place|object[78]	giv|new[78]	coref	11-9
8-16	1459-1467	cleaners	object[78]	new[78]	_	_
8-17	1468-1469	,	_	_	_	_
8-18	1470-1473	and	_	_	_	_
8-19	1474-1480	paints	object	new	_	_
8-20	1481-1482	.	_	_	_	_

#Text=Recent evidence suggests that a significant portion of people exposed to MI developed the capacity for an allergic response , showed exacerbated inflammatory responses , and experienced tissue injury in the skin or lungs after exposure .
9-1	1483-1489	Recent	abstract[80]	new[80]	_	_
9-2	1490-1498	evidence	abstract[80]	new[80]	_	_
9-3	1499-1507	suggests	_	_	_	_
9-4	1508-1512	that	_	_	_	_
9-5	1513-1514	a	person[81]	new[81]	_	_
9-6	1515-1526	significant	person[81]	new[81]	_	_
9-7	1527-1534	portion	person[81]	new[81]	_	_
9-8	1535-1537	of	person[81]	new[81]	_	_
9-9	1538-1544	people	person[81]|person[82]	new[81]|new[82]	_	_
9-10	1545-1552	exposed	person[81]|person[82]	new[81]|new[82]	_	_
9-11	1553-1555	to	person[81]|person[82]	new[81]|new[82]	_	_
9-12	1556-1558	MI	person[81]|person[82]|substance	new[81]|new[82]|giv	coref	10-4
9-13	1559-1568	developed	event|event|event	new|new|new	coref|coref|coref|none|none|none	10-20[98_0]|11-19[109_0]|12-18[118_0]|9-13[0_98]|9-13[0_109]|9-13[0_118]
9-14	1569-1572	the	abstract[84]	new[84]	_	_
9-15	1573-1581	capacity	abstract[84]	new[84]	_	_
9-16	1582-1585	for	abstract[84]	new[84]	_	_
9-17	1586-1588	an	abstract[84]|event[85]	new[84]|new[85]	_	_
9-18	1589-1597	allergic	abstract[84]|event[85]	new[84]|new[85]	_	_
9-19	1598-1606	response	abstract[84]|event[85]	new[84]|new[85]	_	_
9-20	1607-1608	,	_	_	_	_
9-21	1609-1615	showed	_	_	_	_
9-22	1616-1627	exacerbated	event[86]	giv[86]	coref	10-1[93_86]
9-23	1628-1640	inflammatory	event[86]	giv[86]	_	_
9-24	1641-1650	responses	event[86]	giv[86]	_	_
9-25	1651-1652	,	_	_	_	_
9-26	1653-1656	and	_	_	_	_
9-27	1657-1668	experienced	_	_	_	_
9-28	1669-1675	tissue	object|event[88]	giv|new[88]	_	_
9-29	1676-1682	injury	event[88]	new[88]	_	_
9-30	1683-1685	in	event[88]	new[88]	_	_
9-31	1686-1689	the	event[88]|object[89]|object[90]	new[88]|giv[89]|giv[90]	_	_
9-32	1690-1694	skin	event[88]|object[89]|object[90]	new[88]|giv[89]|giv[90]	_	_
9-33	1695-1697	or	event[88]|object[90]	new[88]|giv[90]	_	_
9-34	1698-1703	lungs	event[88]|object[90]|object	new[88]|giv[90]|new	_	_
9-35	1704-1709	after	_	_	_	_
9-36	1710-1718	exposure	event	new	coref	14-16[127_0]
9-37	1719-1720	.	_	_	_	_

#Text=Allergic responses to MI have also been linked to vulvar dermatitis , but no connections between such dermatoses and the later development of vulvar pain have been made in the published clinical literature .
10-1	1721-1729	Allergic	event[93]	giv[93]	_	_
10-2	1730-1739	responses	event[93]	giv[93]	_	_
10-3	1740-1742	to	event[93]	giv[93]	_	_
10-4	1743-1745	MI	event[93]|substance	giv[93]|giv	coref	13-9[122_0]
10-5	1746-1750	have	_	_	_	_
10-6	1751-1755	also	_	_	_	_
10-7	1756-1760	been	_	_	_	_
10-8	1761-1767	linked	_	_	_	_
10-9	1768-1770	to	_	_	_	_
10-10	1771-1777	vulvar	abstract[95]	new[95]	_	_
10-11	1778-1788	dermatitis	abstract[95]	new[95]	_	_
10-12	1789-1790	,	_	_	_	_
10-13	1791-1794	but	_	_	_	_
10-14	1795-1797	no	abstract[96]	new[96]	_	_
10-15	1798-1809	connections	abstract[96]	new[96]	_	_
10-16	1810-1817	between	abstract[96]	new[96]	_	_
10-17	1818-1822	such	abstract[96]|object[97]	new[96]|new[97]	_	_
10-18	1823-1833	dermatoses	abstract[96]|object[97]	new[96]|new[97]	_	_
10-19	1834-1837	and	abstract[96]	new[96]	_	_
10-20	1838-1841	the	abstract[96]|event[98]	new[96]|new[98]	_	_
10-21	1842-1847	later	abstract[96]|event[98]	new[96]|new[98]	_	_
10-22	1848-1859	development	abstract[96]|event[98]	new[96]|new[98]	_	_
10-23	1860-1862	of	abstract[96]|event[98]	new[96]|new[98]	_	_
10-24	1863-1869	vulvar	abstract[96]|event[98]|abstract[99]	new[96]|new[98]|giv[99]	coref	12-21[119_99]
10-25	1870-1874	pain	abstract[96]|event[98]|abstract[99]	new[96]|new[98]|giv[99]	_	_
10-26	1875-1879	have	_	_	_	_
10-27	1880-1884	been	_	_	_	_
10-28	1885-1889	made	_	_	_	_
10-29	1890-1892	in	_	_	_	_
10-30	1893-1896	the	abstract[100]	new[100]	_	_
10-31	1897-1906	published	abstract[100]	new[100]	_	_
10-32	1907-1915	clinical	abstract[100]	new[100]	_	_
10-33	1916-1926	literature	abstract[100]	new[100]	_	_
10-34	1927-1928	.	_	_	_	_

#Text=Recently , Reed and colleagues identified exposures to household and workplace chemicals as a possible risk factor for the development of vulvodynia .
11-1	1929-1937	Recently	_	_	_	_
11-2	1938-1939	,	_	_	_	_
11-3	1940-1944	Reed	person	new	_	_
11-4	1945-1948	and	_	_	_	_
11-5	1949-1959	colleagues	person	new	_	_
11-6	1960-1970	identified	_	_	_	_
11-7	1971-1980	exposures	abstract[103]	new[103]	coref	12-15[116_103]
11-8	1981-1983	to	abstract[103]	new[103]	_	_
11-9	1984-1993	household	abstract[103]|place|substance[106]	new[103]|giv|new[106]	_	_
11-10	1994-1997	and	abstract[103]|substance[106]	new[103]|new[106]	_	_
11-11	1998-2007	workplace	abstract[103]|place|substance[106]	new[103]|new|new[106]	_	_
11-12	2008-2017	chemicals	abstract[103]|substance[106]	new[103]|new[106]	_	_
11-13	2018-2020	as	_	_	_	_
11-14	2021-2022	a	abstract[108]	new[108]	_	_
11-15	2023-2031	possible	abstract[108]	new[108]	_	_
11-16	2032-2036	risk	abstract|abstract[108]	new|new[108]	_	_
11-17	2037-2043	factor	abstract[108]	new[108]	_	_
11-18	2044-2047	for	abstract[108]	new[108]	_	_
11-19	2048-2051	the	abstract[108]|event[109]	new[108]|new[109]	_	_
11-20	2052-2063	development	abstract[108]|event[109]	new[108]|new[109]	_	_
11-21	2064-2066	of	abstract[108]|event[109]	new[108]|new[109]	_	_
11-22	2067-2077	vulvodynia	abstract[108]|event[109]|abstract	new[108]|new[109]|giv	coref	13-7
11-23	2078-2079	.	_	_	_	_

#Text=Our previously published mouse models demonstrated the biological plausibility of the epidemiological link between chemical exposures and the development of genital pain .
12-1	2080-2083	Our	person|abstract[113]	giv|giv[113]	ana	14-1
12-2	2084-2094	previously	abstract[113]	giv[113]	_	_
12-3	2095-2104	published	abstract[113]	giv[113]	_	_
12-4	2105-2110	mouse	animal|abstract[113]	giv|giv[113]	_	_
12-5	2111-2117	models	abstract[113]	giv[113]	_	_
12-6	2118-2130	demonstrated	_	_	_	_
12-7	2131-2134	the	abstract[114]	new[114]	_	_
12-8	2135-2145	biological	abstract[114]	new[114]	_	_
12-9	2146-2158	plausibility	abstract[114]	new[114]	_	_
12-10	2159-2161	of	abstract[114]	new[114]	_	_
12-11	2162-2165	the	abstract[114]|abstract[115]	new[114]|new[115]	coref	13-3[120_115]
12-12	2166-2181	epidemiological	abstract[114]|abstract[115]	new[114]|new[115]	_	_
12-13	2182-2186	link	abstract[114]|abstract[115]	new[114]|new[115]	_	_
12-14	2187-2194	between	abstract[114]|abstract[115]	new[114]|new[115]	_	_
12-15	2195-2203	chemical	abstract[114]|abstract[115]|abstract[116]|abstract[117]	new[114]|new[115]|giv[116]|giv[117]	coref	12-15[117_116]
12-16	2204-2213	exposures	abstract[114]|abstract[115]|abstract[116]|abstract[117]	new[114]|new[115]|giv[116]|giv[117]	_	_
12-17	2214-2217	and	abstract[114]|abstract[115]|abstract[117]	new[114]|new[115]|giv[117]	_	_
12-18	2218-2221	the	abstract[114]|abstract[115]|abstract[117]|event[118]	new[114]|new[115]|giv[117]|new[118]	_	_
12-19	2222-2233	development	abstract[114]|abstract[115]|abstract[117]|event[118]	new[114]|new[115]|giv[117]|new[118]	_	_
12-20	2234-2236	of	abstract[114]|abstract[115]|abstract[117]|event[118]	new[114]|new[115]|giv[117]|new[118]	_	_
12-21	2237-2244	genital	abstract[114]|abstract[115]|abstract[117]|event[118]|abstract[119]	new[114]|new[115]|giv[117]|new[118]|giv[119]	coref	14-21[129_119]
12-22	2245-2249	pain	abstract[114]|abstract[115]|abstract[117]|event[118]|abstract[119]	new[114]|new[115]|giv[117]|new[118]|giv[119]	_	_
12-23	2250-2251	.	_	_	_	_

#Text=However , a specific link between vulvodynia and a known environmental chemical does not yet exist .
13-1	2252-2259	However	_	_	_	_
13-2	2260-2261	,	_	_	_	_
13-3	2262-2263	a	abstract[120]	giv[120]	_	_
13-4	2264-2272	specific	abstract[120]	giv[120]	_	_
13-5	2273-2277	link	abstract[120]	giv[120]	_	_
13-6	2278-2285	between	abstract[120]	giv[120]	_	_
13-7	2286-2296	vulvodynia	abstract[120]|abstract	giv[120]|giv	_	_
13-8	2297-2300	and	abstract[120]	giv[120]	_	_
13-9	2301-2302	a	abstract[120]|substance[122]	giv[120]|giv[122]	coref	14-4[0_122]
13-10	2303-2308	known	abstract[120]|substance[122]	giv[120]|giv[122]	_	_
13-11	2309-2322	environmental	abstract[120]|substance[122]	giv[120]|giv[122]	_	_
13-12	2323-2331	chemical	abstract[120]|substance[122]	giv[120]|giv[122]	_	_
13-13	2332-2336	does	_	_	_	_
13-14	2337-2340	not	_	_	_	_
13-15	2341-2344	yet	_	_	_	_
13-16	2345-2350	exist	_	_	_	_
13-17	2351-2352	.	_	_	_	_

#Text=We suggest that MI is a plausible candidate for an environmental irritant/allergen , and that exposure to MI might drive allergy-provoked pain .
14-1	2353-2355	We	person	giv	ana	15-3
14-2	2356-2363	suggest	_	_	_	_
14-3	2364-2368	that	_	_	_	_
14-4	2369-2371	MI	substance	giv	coref	14-18
14-5	2372-2374	is	_	_	_	_
14-6	2375-2376	a	person[125]	new[125]	_	_
14-7	2377-2386	plausible	person[125]	new[125]	_	_
14-8	2387-2396	candidate	person[125]	new[125]	_	_
14-9	2397-2400	for	person[125]	new[125]	_	_
14-10	2401-2403	an	person[125]|abstract[126]	new[125]|new[126]	_	_
14-11	2404-2417	environmental	person[125]|abstract[126]	new[125]|new[126]	_	_
14-12	2418-2435	irritant/allergen	person[125]|abstract[126]	new[125]|new[126]	_	_
14-13	2436-2437	,	_	_	_	_
14-14	2438-2441	and	_	_	_	_
14-15	2442-2446	that	_	_	_	_
14-16	2447-2455	exposure	event[127]	giv[127]	_	_
14-17	2456-2458	to	event[127]	giv[127]	_	_
14-18	2459-2461	MI	event[127]|substance	giv[127]|giv	coref	15-6[131_0]
14-19	2462-2467	might	_	_	_	_
14-20	2468-2473	drive	_	_	_	_
14-21	2474-2490	allergy-provoked	abstract[129]	giv[129]	_	_
14-22	2491-2495	pain	abstract[129]	giv[129]	_	_
14-23	2496-2497	.	_	_	_	_

#Text=Here , we repeatedly applied MI dissolved in saline ( a surrogate for water-based cleansers that typically contain MI as a preservative ) topically within the vaginal canals of mice and characterized consequent allergic inflammation , accumulation of mast cells , and ano-genital sensitivity to pressure .
15-1	2498-2502	Here	_	_	_	_
15-2	2503-2504	,	_	_	_	_
15-3	2505-2507	we	person	giv	ana	16-1
15-4	2508-2518	repeatedly	_	_	_	_
15-5	2519-2526	applied	_	_	_	_
15-6	2527-2529	MI	substance[131]	giv[131]	coref	15-19[0_131]
15-7	2530-2539	dissolved	substance[131]	giv[131]	_	_
15-8	2540-2542	in	substance[131]	giv[131]	_	_
15-9	2543-2549	saline	substance[131]|substance	giv[131]|new	_	_
15-10	2550-2551	(	_	_	_	_
15-11	2552-2553	a	abstract[133]	new[133]	_	_
15-12	2554-2563	surrogate	abstract[133]	new[133]	_	_
15-13	2564-2567	for	abstract[133]	new[133]	_	_
15-14	2568-2579	water-based	abstract[133]|substance[134]	new[133]|new[134]	_	_
15-15	2580-2589	cleansers	abstract[133]|substance[134]	new[133]|new[134]	_	_
15-16	2590-2594	that	abstract[133]|substance[134]	new[133]|new[134]	_	_
15-17	2595-2604	typically	abstract[133]|substance[134]	new[133]|new[134]	_	_
15-18	2605-2612	contain	abstract[133]|substance[134]	new[133]|new[134]	_	_
15-19	2613-2615	MI	abstract[133]|substance[134]|substance	new[133]|new[134]|giv	coref	15-21[136_0]
15-20	2616-2618	as	abstract[133]|substance[134]	new[133]|new[134]	_	_
15-21	2619-2620	a	abstract[133]|substance[134]|substance[136]	new[133]|new[134]|giv[136]	_	_
15-22	2621-2633	preservative	abstract[133]|substance[134]|substance[136]	new[133]|new[134]|giv[136]	_	_
15-23	2634-2635	)	_	_	_	_
15-24	2636-2645	topically	_	_	_	_
15-25	2646-2652	within	_	_	_	_
15-26	2653-2656	the	place[137]	new[137]	_	_
15-27	2657-2664	vaginal	place[137]	new[137]	_	_
15-28	2665-2671	canals	place[137]	new[137]	_	_
15-29	2672-2674	of	place[137]	new[137]	_	_
15-30	2675-2679	mice	place[137]|animal	new[137]|giv	_	_
15-31	2680-2683	and	_	_	_	_
15-32	2684-2697	characterized	_	_	_	_
15-33	2698-2708	consequent	abstract[139]	giv[139]	_	_
15-34	2709-2717	allergic	abstract[139]	giv[139]	_	_
15-35	2718-2730	inflammation	abstract[139]	giv[139]	_	_
15-36	2731-2732	,	_	_	_	_
15-37	2733-2745	accumulation	event[140]	new[140]	_	_
15-38	2746-2748	of	event[140]	new[140]	_	_
15-39	2749-2753	mast	event[140]|object|object[142]	new[140]|giv|giv[142]	coref	16-20
15-40	2754-2759	cells	event[140]|object[142]	new[140]|giv[142]	_	_
15-41	2760-2761	,	_	_	_	_
15-42	2762-2765	and	_	_	_	_
15-43	2766-2777	ano-genital	abstract[143]	giv[143]	coref	16-24[154_143]
15-44	2778-2789	sensitivity	abstract[143]	giv[143]	_	_
15-45	2790-2792	to	abstract[143]	giv[143]	_	_
15-46	2793-2801	pressure	abstract[143]|abstract	giv[143]|new	_	_
15-47	2802-2803	.	_	_	_	_

#Text=We also assessed the effects of therapeutic and preventive administration of topical THC treatments in the vaginal canal on mast cell abundance and painful sensitivity .
16-1	2804-2806	We	person	giv	_	_
16-2	2807-2811	also	_	_	_	_
16-3	2812-2820	assessed	_	_	_	_
16-4	2821-2824	the	abstract[146]	new[146]	_	_
16-5	2825-2832	effects	abstract[146]	new[146]	_	_
16-6	2833-2835	of	abstract[146]	new[146]	_	_
16-7	2836-2847	therapeutic	abstract[146]|event[147]	new[146]|new[147]	_	_
16-8	2848-2851	and	abstract[146]|event[147]	new[146]|new[147]	_	_
16-9	2852-2862	preventive	abstract[146]|event[147]	new[146]|new[147]	_	_
16-10	2863-2877	administration	abstract[146]|event[147]	new[146]|new[147]	_	_
16-11	2878-2880	of	abstract[146]|event[147]	new[146]|new[147]	_	_
16-12	2881-2888	topical	abstract[146]|event[147]|abstract[149]	new[146]|new[147]|new[149]	_	_
16-13	2889-2892	THC	abstract[146]|event[147]|substance|abstract[149]	new[146]|new[147]|giv|new[149]	_	_
16-14	2893-2903	treatments	abstract[146]|event[147]|abstract[149]	new[146]|new[147]|new[149]	_	_
16-15	2904-2906	in	abstract[146]|event[147]|abstract[149]	new[146]|new[147]|new[149]	_	_
16-16	2907-2910	the	abstract[146]|event[147]|abstract[149]|place[150]	new[146]|new[147]|new[149]|giv[150]	_	_
16-17	2911-2918	vaginal	abstract[146]|event[147]|abstract[149]|place[150]	new[146]|new[147]|new[149]|giv[150]	_	_
16-18	2919-2924	canal	abstract[146]|event[147]|abstract[149]|place[150]	new[146]|new[147]|new[149]|giv[150]	_	_
16-19	2925-2927	on	abstract[146]	new[146]	_	_
16-20	2928-2932	mast	abstract[146]|object|place[152]|abstract[153]	new[146]|giv|new[152]|new[153]	_	_
16-21	2933-2937	cell	abstract[146]|place[152]|abstract[153]	new[146]|new[152]|new[153]	_	_
16-22	2938-2947	abundance	abstract[146]|abstract[153]	new[146]|new[153]	_	_
16-23	2948-2951	and	abstract[146]	new[146]	_	_
16-24	2952-2959	painful	abstract[146]|abstract[154]	new[146]|giv[154]	_	_
16-25	2960-2971	sensitivity	abstract[146]|abstract[154]	new[146]|giv[154]	_	_
16-26	2972-2973	.	_	_	_	_
